Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jval.2013.09.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DREAM: an adaptive, randomised, placebo-controlled trial of duloxetine for reducing leg pain in people with chronic sciatica-trial protocol.
BMJ Open
December 2024
Institute for Musculoskeletal Health, Sydney Local Health District, Sydney, New South Wales, Australia.
Introduction: Sciatica is a debilitating condition that often becomes chronic, and for which there are few effective treatment options. Treatments such as the anti-depressant duloxetine have shown promise, but the evidence is inconclusive. We are describing a high quality, definitive trial to investigate the efficacy, safety and cost-effectiveness of duloxetine in chronic sciatica.
View Article and Find Full Text PDFCost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective.
Expert Rev Pharmacoecon Outcomes Res
October 2024
Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Objectives: To estimate the cost-utility of duloxetine compared with that of a placebo, common traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors for the treatment of osteoarthritis (OA) from a Chinese healthcare perspective.
Methods: A Markov model was constructed. The costs and utility inputs were obtained from the database and published literature.
Effectiveness of Antidepressants in Combination with Psychotherapy.
J Ment Health Policy Econ
March 2024
Department of Health Administration and Policy, George Mason University, Fairfax, VA 19122, USA,
Background: Consensus-guidelines for prescribing antidepressants recommend that clinicians should be vigilant to match antidepressants to patient's medical history but provide no specific advice on which antidepressant is best for a given medical history.
Aims Of The Study: For patients with major depression who are in psychotherapy, this study provides an empirically derived guideline for prescribing antidepressant medications that fit patients' medical history.
Methods: This retrospective, observational, cohort study analyzed a large insurance database of 3,678,082 patients.
Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT.
Health Technol Assess
October 2022
Department of Oncology and Human Metabolism, Medical School, University of Sheffield, Sheffield, UK.
Background: The mainstay of treatment for diabetic peripheral neuropathic pain is pharmacotherapy, but the current National Institute for Health and Care Excellence guideline is not based on robust evidence, as the treatments and their combinations have not been directly compared.
Objectives: To determine the most clinically beneficial, cost-effective and tolerated treatment pathway for diabetic peripheral neuropathic pain.
Design: A randomised crossover trial with health economic analysis.
No Added Value of Duloxetine in Patients With Chronic Pain due to Hip or Knee Osteoarthritis: A Cluster-Randomized Trial.
Arthritis Rheumatol
May 2022
Erasmus University Medical Center, Rotterdam, The Netherlands.
Objective: To assess the effectiveness of duloxetine in addition to usual care in patients with chronic osteoarthritis (OA) pain. The cost-effectiveness and whether the presence of symptoms of centralized pain alters the response to duloxetine were secondary objectives.
Methods: We conducted an open-label, cluster-randomized trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!